OncoPan®: An NGS-Based Screening Methodology to Identify Molecular Markers for Therapy and Risk Assessment in Pancreatic Ductal Adenocarcinoma
Authors:
- Maria Grazia TibilettiMaria Grazia Tibiletti
- Ileana CarnevaliICIleana Carnevali
- Valeria PensottiVPValeria Pensotti
- Anna Maria ChiaravalliACAnna Maria Chiaravalli
- Sofia FacchiSFSofia Facchi
- Sara VolorioSVSara Volorio
- Frederique MarietteFMFrederique Mariette
- Paolo MarianiPMPaolo Mariani
- Stefano FortuzziSFStefano Fortuzzi
- Marco Alessandro PierottiMPMarco Alessandro Pierotti
- Fausto SessaFSFausto Sessa
Open Access
- 23 May 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (5) , 1208
Abstract
Pancreatic cancer has a high morbidity and mortality with the majority being PC ductal adenocarcinomas (PDAC). Whole genome sequencing provides a wide description of genomic events involved in pancreatic carcinogenesis and identifies putative biomarkers for new therapeutic approaches. However, currently, there are no approved treatments targeting driver mutations in PDAC that could produce clinical benefit for PDAC patients. A proportion of 5–10% of PDAC have a hereditary origin involving germline variants of homologous recombination genes, such as Mismatch Repair (MMR), STK11 and CDKN2A genes. Very recently, BRCA genes have been demonstrated as a useful biomarker for PARP-inhibitor (PARPi) treatments. In this study, a series of 21 FFPE PDACs were analyzed using OncoPan®, a strategic next-generation sequencing (NGS) panel of 37 genes, useful for identification of therapeutic targets and inherited cancer syndromes. Interestingly, this approach, successful also on minute pancreatic specimens, identified biomarkers for personalized therapy in five PDAC patients, including two cases with HER2 amplification and three cases with mutations in HR genes (BRCA1, BRCA2 and FANCM) and potentially eligible to PARPi therapy. Molecular analysis on normal tissue identified one PDAC patient as a carrier of a germline BRCA1 pathogenetic variant and, noteworthy, this patient was a member of a family affected by inherited breast and ovarian cancer conditions. This study demonstrates that the OncoPan® NGS-based panel constitutes an efficient methodology for the molecular profiling of PDAC, suitable for identifying molecular markers both for therapy and risk assessment. Our data demonstrate the feasibility and utility of these NGS analysis in the routine setting of PDAC molecular characterization.Keywords
This publication has 27 references indexed in Scilit:
- HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical OncologyJournal of Clinical Oncology, 2017
- HGVS Recommendations for the Description of Sequence Variants: 2016 UpdateHuman Mutation, 2016
- TP53 alterations in pancreatic acinar cell carcinoma: new insights into the molecular pathology of this rare cancerVirchows Archiv, 2015
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- Whole genomes redefine the mutational landscape of pancreatic cancerNature, 2015
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- CDKN2A is the main susceptibility gene in Italian pancreatic cancer familiesJournal of Medical Genetics, 2012
- Susceptibility Loci Associated with Prostate Cancer Progression and MortalityClinical Cancer Research, 2010
- Functional characterization of the RAD51D E233G genetic variantPharmacogenetics and Genomics, 2009
- Assessment of a HER2 scoring system for gastric cancer: results from a validation studyHistopathology, 2008